NewsBenzingaCORRECTION : Amprius Technologies : le BPA GAAP pour l’exercice 2026 devrait être inférieur à (0,07 $) contre (0,08 $) estimé ; prévoit un chiffre d’affaires 2026 de 145,000 M$ contre 140,640 M$ estimés CORRECTION : Amprius Technologies : le BPA GAAP pour l’exercice 2026 devrait être inférieur à (0,07 $) contre (0,08 $) estimé ; prévoit un chiffre d’affaires 2026 de 145,000 M$ contre 140,640 M$ estimés Benzinga 2026.11.10 22:12 (GMT+0) Open on Benzinga Other news OpenAI Details NATO Use of Its Cybersecurity Models 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' A-Share Close: ChiNext Index Down Over 1% After Intraday Reversal, More Than 4,100 Stocks Fall Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen